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S224 Oral Presentations(36%) were associated with less OM (HR 0.78; P 5 .04) and NRM
(HR 0.70; P 5 .02).
For the first time in HSCT, this study demonstrates the impact of
3DL1 allotypes inHSCT, where combinations of 3DL1-high and their
high affinity Bw4 alleles in the donor are associated with higher relapse
andOMin patients. Conversely, donor 3DS1 is associatedwith lessOM
and NRM. These data offer insights to differential controls of NK bi-
ology inHSCT and support not only KIR genotyping but KIR allotyp-
ing in order to select donors with the best KIR-HLA combinations to
maximize leukemic control while minimizing unwanted toxicities.57
HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING ANTI-
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Allogeneic hematopoietic cell transplant (HCT) is a widely used
therapy for hematologic malignancy. It is important to give the op-
tion of HCT to patients without an HLA-matched donor; this is
most acute for ethnic minorities. Haploidentical HCT may offer
the best or only chance for cure but often fails due to persistant ma-
lignancy or fatal toxicity. It is important to improve disease control
without increased toxicity of the regimen. We have shown that
CD45 radioimmunotherapy (RIT) delivers radiation to leukemic
sites, sparing normal organs. We hypothesize haploidentical HCT
may be enhanced via CD45RIT bymaximizing delivery to target tis-
sue with minimal toxicity by reducing total-body irradiation (TBI)
and chemotherapy.We performed studies to find the maximal inten-
sity of anti-leukemic RIT combined with haploidentical HCT while
preserving graft-versus-leukemia effects. We established an HCT
regimen in B6SJLF1/J mice (H-2Db haplotype) conditioned with
fludarabine (FLU, days -6 to -2), followed by TBI (250, 500, 750
cGy; day -1). Mice received 15 million donor (CB6F1/J, H-2Dd)
BM cells (day 0), then cyclophosphamide (CY) for graft-versus-
host disease (GvHD) prophylaxis (day +2). Chimerism was TBI
dose-dependent; mice receiving $500 cGy were fully chimeric 4
weeks post-HCT, persisting $8 months. We then treated
B6SJLF1/J mice with or without FLU and 200-400 mCi of 90Y-la-
beled anti-murine CD45 Ab (30F11, day -3), followed by 15 million
donor BM cells (day 0) and CY (day +2). All mice receiving 200 or
300 mCi 90Y-CD45Ab survived 30 days after HCTwith no evidence
of toxicity or GvHD. Four of 10 mice receiving 400 mCi 90Y-CD45
Ab died by day 25 due to toxicity. At day 25 blood was taken to detect
chimerism via flow cytometry. Three of 5 mice that received 200 mCi
90Y-CD45 Ab and FLU showed chimerism with 23-77% CD8+ T-
cells expressing H-2Dd. Four of 5 (80%) mice receiving 300 mCi
90Y-30F11 and 2/3 (67%) receiving 400 mCi 90Y-30F11, in the pres-
ence of FLU, were chimeric with 22-89% and 25-64%CD8+ donor
cells, respectively. Mice receiving 200, 300, or 400 mCi 90Y-CD45
Ab without FLU were chimeric with 10-71% donor cells in 4/5
(80%), 2/5 (40%) and 1/4 (25%) mice, respectively. These data sug-
gest anti-CD45 RIT may be a well-tolerated regimen allowing en-
graftment of haploidentical marrow without TBI and
chemotherapy. Current studies testing pretargeted RIT may im-
prove targeting of malignant CD45+ cells with reduced TBI and
FLU, and increased therapeutic index.IMMUNE RECONSTITUTION58
EARLY POST-TRANSPLANT WHOLE TUMOR CELL-BASED VACCINATION
ALTERS THE KINETICS OF T CELL RECONSTITUTION
Burkhardt, U.E.1, Desmarais, C.2, Robins, H.S.2, Wu, D.1, Wong, J.1,
Neuberg, D.1, Alyea, E.P.1, Soiffer, R.J.1,Wu, C.J.1 1Dana-Farber Can-
cer Institute, Boston, MA; 2Adaptive TCR Technologies, Seattle, WAWhole tumor cell-based vaccines administered in the early post-
transplant (HSCT) setting are a promising approach to enhance
graft-versus-leukemia responses. Our previous studies described
the detection of increasedCD8+T cells with specificity for autologous
chronic lymphocytic leukemia (CLL) cells in association with attain-
ment of molecular remission within 6 months post-HSCT that devel-
oped following early-post transplant tumor vaccination (initiating at
day 30-45). The series of vaccines were comprised of irradiated autol-
ogous tumor admixed with irradiated GM-CSF secreting bystander
cells. It is unknown how this early post-transplant intervention shapes
the reconstituting donor T cell repertoire. One approach to character-
ize this is through examining the kinetics of recovery of T cell receptor
(TCR) beta-chain diversity using recently developed methodologies
that apply deep sequencing techniques for the analysis of the highly
variable complementarity-determining region 3 (CDR3) of the
TCR. We therefore isolated na€ıve and memory T cells from the
CD8 andCD4 compartments from 12 patients (6with vaccine, 6 with-
out) at time points informative for thymic-independent (early; 4month
post-transplant) and thymic-dependent (late; 1 year post-transplant) T
cell immune recovery. The isolated cell subsets directly underwent
PCR amplification of the CDR3 region to generate a template library
that was then sequenced using the IlluminaGA2 system.We obtained
a median of 24,191 productive reads per sample (range 0-8,900,000).
To evaluate theTCRdiversity, we calculated the normalized probabil-
ity distribution (‘entropy’) of eachT cell compartment.Overall, we ob-
served that the 6 vaccinated subjects demonstrated a higher
normalized entropy at day 120 (p 5 0.008) and more unique CDR3
sequences (one-tailed t-test with unequal variance: p 5 0.03) com-
pared to non-vaccinated subjects. In particular, CD8+ memory and
na€ıve cells exhibited greater TCR diversity at days 120 and 365 in vac-
cinated than in non-vaccinated individuals. These results suggest that
early post-transplant vaccination exerts an active role in shaping T cell
reconstitution.Ongoing analyses focus on the integration ofTCR rep-
ertoire data with the assessment of minimal residue disease, immuno-
phenotyping and TCR excision circle (TREC) analysis. The results
gained within this study provide us with critical information as we for-
mulate the next generation of post-transplant cancer vaccines.59
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT/Cy) PRESERVES EFFEC-
TOR (Teff) AND REGULATORY (Treg) T CELLS DURING EARLY IMMUNE
RECONSTITUTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTA-
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Emerging clinical data suggest that high-dose PT/Cy is effective
in preventing both acute and chronic GVHD, but the mechanisms
accounting for these effects have not been fully characterized. We
hypothesized that PT/Cy prevents acuteGVHD (aGVHD) by selec-
tively depleting highly proliferative alloreactive T cells stimulated
early after transplant, while sparing Tregs. We analyzed the pheno-
typic reconstitution of CD4+ T cells at days 30 and 60 after trans-
plant in a cohort of 47 consecutive patients (median age 50) that
received HLA-matched allografts and PT/Cy as sole GVHD pro-
phylaxis. CD4+Foxp3+ T cells were partitioned into three pheno-
typic fractions (Fr) with distinct functions: CD45RA+Foxp3+lo (Fr
I), CD45RA-Foxp3+hi (Fr II), and CD45RA-Foxp3+lo (Fr III), repre-
senting naive Tregs, activated Tregs, and non-suppressive, cytokine-
secreting Teff, respectively. In both patients with and without
aGHVD, Teff (Fr III) percentages were increased compared with
healthy donors (p 5 0.004), and were higher in patients with
aGVHD compared with patients without aGVHD (p5 0.0003). In-
terestingly, patients with aGVHD also had higher percentages of ac-
tivated Tregs (Fr II, p 5 0.01) compared with patients without
aGVHD. These relative increases in Fr II and III persisted despite
steroid-induced lymphopenia. The relative expansion of Tregs in pa-
tients with aGVHD was an unexpected finding, since aGVHD is as-
sociated with lower Tregs in studies using traditional GVHD
prophylaxis incorporating calcineurin inhibitors (CNIs). To assess
differential effects of PT/Cy and CNI on T cell reconstitution in
Oral Presentations S225alloreactive responses, mixed lymphocyte reactions (MLR) were
performed (n 5 6). High-dose, activated cyclophosphamide (mafos-
famide) given 3 days after the start of MLR caused increases in Fr
I-III at 7 days (Fr II, p\0.0001; Fr III, p 5 0.0002), while cyclo-
sporine-treated cells had similar to lower levels of these fractions
compared with controls. The addition of mafosfamide at day 3 to
cyclosporine-cultured cells in MLR caused similar increases in Fr
I and III as seen with mafosfamide alone, but the Fr II increase
was no longer significant. In summary, T cell reconstitution in pa-
tients treated with PT/Cy differs from that seen with CNI-based
GVHD prophylaxis. For patients treated with PT/Cy who still de-
velop aGVHD, relative expansion of Tregs may be a critical com-
pensatory mechanism accounting for the remarkably low incidence
of chronic GVHD seen in these patients.60
IMMUNE INSUFFICIENCY AFTER EXPERIMENTAL TRANSPLANTATION IS
DUE TO DEFECTIVE ANTIGEN PRESENTATION WITHIN DENDRITIC
CELL SUBSETS
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Alloreactivity after transplantation is associated with profound im-
mune suppression and consequent opportunistic infection results in
high morbidity and mortality. This immune suppression is most
dramatic during graft–versus–host disease (GVHD) after bone
marrow transplantation (BMT) where an inflammatory cytokine
storm dominates. We used the B6 (I-Ab/I-E-/-)/ BALB/c (I-Ad/
I-Ed) BMT model to track antigen specific responses induced by
donor APC. Bone marrow grafts were either T cell depleted
(non-GVHD) or replete (GVHD) and derived from wild-type or
CD11c.OVA transgenic (Tg) donors. We determined the extent
of antigen presentation by quantifying CFSE dilution of adoptively
transferred TEa Tg T cells (which respond to host I-Ed presented
in donor I-Ab) and OT-II Tg T cells (which respond to OVA-de-
rived peptide). GVHD induced a marked defect in antigen presen-
tation of both alloantigen and nominal antigens. By utilizing
CD11c.DTR Tg grafts and DC-depletion with diphtheria toxin
we demonstrated that conventional DC (cDC) were the critical do-
nor cell presenting alloantigen during GVHD. Surprisingly, num-
ber, phenotype and phagocytic/proteolytic function of these cells
were all equivalent in the GVHD and non-GVHD settings. How-
ever, cDC from mice with GVHD failed to present OVA Ag within
MHC II to OT-II T cells, confirming a DC specific defect during
GVHD. In contrast, both classical and cross presentation within
MHC class I remained intact. Analysis of cDC subsets revealed
that the CD8neg donor cDC were the critical cell population for
class-II mediated Ag presentation and that this specific sub-popula-
tion was defective during GVHD. This defect is two-fold, and is
caused by both a functional impairment in class II presentation
in the CD4negCD8neg cDC population, and a concurrent failure
of development in the CD4+CD8neg population. Importantly, the
functional defect in antigen processing within MHC class II can
be reversed by TNF inhibition or the adoptive transfer of donor
cDC generated in the absence of inflammation.61
TOLERANCE ASSOCIATED GENE EXPRESSION FOLLOWING ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Pidala, J.1, Bloom, G.2, Eschrich, S.2, Enkemann, S.3, Anasetti, C.1 1Mof-
fitt Cancer Center, Tampa, FL; 2Moffitt Cancer Center; 3Moffitt Cancer
CenterBackground: Elucidation of immune tolerance-associated biomarkers
may facilitate personalizedmanagement of immune suppression (IS) fol-
lowing allogeneic hematopoietic cell transplantation (HCT).
Methods: We have performed an analysis of differential gene ex-
pression between tolerant, non-tolerant, and healthy control sub-
jects. Tolerant cases (n 5 17) were HCT recipients off IS for at
least 6 months without any manifestations of acute or chronic graft
vs. host disease (GVHD). Non-tolerant comparators (n 5 16) were
matched for age (+/- 5 years) and time from date of HCT (+/- 6
months), but failed to discontinue IS due to GVHD. Published gene
expression data from healthy volunteer subjects (n5 9) served as con-
trol. Clinical data gathered on all tolerant (TOL) and non-Tolerant
(non-TOL) cases included patient demographic and HCT informa-
tion, comprehensive review of acute and chronic GVHD activity,
and history of IS drug therapy. From freshly obtained peripheral blood
samples, two analyses were performed: First, from total peripheral
bloodmononuclear cells (PBMC), cell populations were characterized
by surface phenotype with flow cytometry. Second, RNA was ex-
tracted from fresh PBMC to serve as themRNA source for microarray
analysis using the Affymetrix Human U133 plus 2.0 array.
Results: Demographic and transplantation variables did not signif-
icantly differ between groups. We did not detect significant differ-
ences in cell composition (ab T cells, gd T cells, regulatory T
cells, NKT cells, NK cells, B cells, monocytes, type 1 and type 2 den-
dritic cells) betweenTOLand non-TOLgroups.We first conducted
a two group (TOL vs. non-TOL) comparison of gene expression.
SAM analysis with 300 permutations, $ 1.5-fold change, and 10%
false discovery rate identified 231 genes up- and 412 down-regulated
in Tol vs. non-Tol groups. Pathway analysis (MetaCore byGeneGo)
mapped involved genes to immune response pathways involving T
cell (TCR receptor signaling, NF-AT) and NK cell (DAP12,
NKG2D, CD16) signaling. Construction of a 3-way (TOL vs.
non-TOL vs. control) classifier resulted in a weighted accuracy of
88% for leave 10% out cross-validation.
Conclusion: These data demonstrate differential gene expression
among tolerant HCT recipients distinct from both non-tolerant
and control subjects, and support a classifier that can accurately iden-
tify the tolerant phenotype. Confirmation of these results will re-
quire a prospective trial of IS discontinuation.62
THYMIC FUNCTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
IS DEPENDENT ON GRAFT SOURCE AND PREDICTIVE OF LONG TERM
SURVIVAL
Sairafi, D.1,2, Mattsson, J.1,2, Uhlin, M.1,2, Uzunel, M.2 1Karolinska
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Background: T-cell function is defective after allogeneic stem cell
transplantation (ASCT). This has a significant clinical impact by in-
creasing patients’ susceptibility to infections, thus reducing survival.
One way to assess thymic output of T-cells is by measuring the level
of T-cell receptor excision circles (TRECs).
Methods:This retrospective study involved 210 patients with hema-
tological malignancies. TREC levels in separated T-cells were mea-
sured at 6 time-points during the first 24-months after ASCT, using
quantitative real-time PCR.
Results:The use of bonemarrow grafts rather than peripheral blood
stem cell grafts showed a significant correlation with higher TREC
levels .6 months after ASCT (p\0.001). Treatment with anti-thy-
mocyte globulin was correlated with lower TREC levels#6 months
post-ASCT (p\0.001). The group of patients with TREC levels
above median 3 months post-ASCT had a superior overall survival;
80% vs. 56% (p5 0.002), and lower transplantation-related mortal-
ity; 7% vs. 21% (p 5 0.01).
Conclusion: These results give further evidence that thymic func-
tion has an important role in the reconstitution of the T-cell pool af-
ter ASCT. We have also shown that factors related to the ASCT
treatment itself, such as graft source and in-vivo T-cell depletion,
may have a significant effect on TREC levels, and can subsequently
affect outcome. These findings also support the use of TREC mea-
surement as part of the standard repertoire of immunological mon-
itoring after ASCT.
